Showing posts with label hCG. Show all posts
Showing posts with label hCG. Show all posts

Wednesday, September 28, 2016

Morning Sickness in early pregnancy linked to lower risk of miscarriages and still births.

Nausea and vomiting in early pregnancy affects 50-80% of pregnant women. Researchers have linked its etiology to imbalance in carbohydrate metabolism, rising hormonal levels in pregnancy, psychosomatic factors  evolutionary survival adaptation which protects pregnant mothers and their babies from food poisoning

 Few  observational studies in the past have documented that incidence of pregnancy loss is lower in patients who have morning sickness in first trimester.

A new study published in the in the journal JAMA Internal Medicine[1] found that women who suffer from nausea and vomiting in the first trimester have 50% less chance of miscarriage.

The study is a result of secondary data analysis of a Randomized Control Trial (RCT) examining Effects of Aspirin in Gestation and Reproduction (EAGeR) Trial.[2] The EAGeR study is a multi-site, double-blinded randomized trial designed to assess the effects of low-dose aspirin on implantation and pregnancy outcome carried out by researchers at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and other institutions.

The secondary analysis was limited to women who had a pregnancy confirmed by positive human chorionic gonadotropin (hCG) test, had a history of at least one pregnancy loss. A total of 797 study subjects was recruited. The women kept a daily diary for nausea and vomiting from week 2 to week 8 of pregnancy, and monthly thereafter.

Out of 797 pregnancies, 188 ended in loss (23.6%), and at the end of 8 weeks about 57.3 percent of the women reported experiencing nausea and 26.6 percent reported nausea with vomiting. 
In this cohort of women, it was seen that nausea alone or nausea with vomiting during pregnancy were associated with nearly 50%-75% reduction in the risk for pregnancy loss. When the analysis was done for peri-implantation pregnancy loss, the results were similar but they were not statistically significant.

Younger women (age <25 years) suffered much more with nausea and vomiting as compared to older women.

The association persisted even after accounting for confounding factors like maternal stress, alcohol intake, caffeine intake, smoking, fetal sex, multiple-fetal gestation, and karyotype.

Stefanie Hinkle, the lead author and a researcher at the national institute said "Our study evaluates symptoms from the earliest weeks of pregnancy, immediately after conception, and confirms that there is a protective association between nausea and vomiting and a lower risk of pregnancy loss.” But, was not sure whether the study results could be applied to primigravida.

She also went to stress that women with no nausea or vomiting should not be alarmed as a result of this study. "Every pregnancy is different and just because they don't have symptoms doesn't mean they're going to have a pregnancy loss," Hinkle said.[3]

The study was also followed by an accompanying editorial by Siripanth Nippita, MD, and Laura E. Dodge, ScD, MPH, from the Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center. They said "This study's contribution to the existing literature is valuable for several reasons. It builds on a prior cohort study by Sapra et al and similarly enrolled a large sample of women before conception."

They further quote “The widespread availability of sensitive urine hCG tests coupled with real-time electronic data capture using mobile phone apps or similar technology has the potential to improve data quality and eliminate recall bias. Given these methodologic advantages over previous investigations, we hope that such studies can further deepen our understanding of the underlying causes of [nausea and vomiting in pregnancy]."

The researchers also urged women with nausea and vomiting in pregnancy to seek medical consultation since it negatively affects the quality of life.




[1] http://archinte.jamanetwork.com/article.aspx?articleid=2553283
[2] http://grantome.com/grant/NIH/ZIA-HD008795-08
[3] Stefanie N. Hinkle, Sunni L. Mumford, Katherine L. Grantz, Robert M. Silver, Emily M. Mitchell, Lindsey A. Sjaarda, Rose G. Radin, Neil J. Perkins, Noya Galai, Enrique F. Schisterman. Association of Nausea and Vomiting During Pregnancy With Pregnancy LossJAMA Internal Medicine, 2016; DOI: 10.1001/jamainternmed.2016.5641

Friday, February 19, 2016

Serum Biomarkers to predict outcome in women with threatened abortion: A systemic review and diagnostic accuracy meta-analysis.




Threatened abortion approximately affect 20% of pregnancies and 50% of those will end up in miscarriage.  It has also been associated with poor obstetric outcome such as preterm labor, low lying placenta, low birth weight and PROM.

The uncertainty of prognosis makes it a challenging task for healthcare professionals.Various biomarkers have been used, with variable results to predict the prognosis of bleeding in early pregnancy.

This systemic review and meta-analysis was published in the forthcoming issue of Human Reproduction update, it aims to determine the diagnostic accuracy of various biomarkers.

A total of 19 studies were found after electronic searching of databases to determine outcomes for women with threatened abortion at 5–23 weeks gestational age.

15 studies (including 1263 women) were found eligible using QUADAS-2 (Quality Assessment for Diagnostic Accuracy Studies-2: A Revised Tool) to include in the qualitative data assessment.

The biomarkers that were looked into included serum progesterone, hCG, pregnancy associated plasma protein A, estradiol and cancer antigen 125 (CA 125).

Interestingly, serum CA 125 appeared to be the most promising marker (n = 648 women, 7 studies), whereas serum progesterone and hCG are less useful once fetal viability is established.

CA-125 is a glycoprotein and its origin is uncertain during pregnancy. It arises during the first trimester and return to a non-pregnancy range in late pregnancy.

CA 125 showed a sensitivity of 90% (95% confidence interval (CI) 83–94%), specificity of 88% (95% CI 79–93%), positive likelihood ratio of 7.86 (95% CI 4.23–14.60) and negative likelihood ratio of 0.10 (95% CI 0.06–0.20). The inverse of negative likelihood ratio was 9.31 (95% CI 5–17.1) indicating that a negative test is likely to identify those who are likely to continue with the pregnancy.

Nevertheless, when vaginal bleeding had been present for 3 days or more and there was high maternal serum CA125 activity, the abortion risk was found to be 100%.

Since this was a qualitative analysis, no cut-off value for CA125 was determined but in most studies patients who eventually aborted had values of CA-125 more than 125 IU/ml while the control had a value not more than 93 IU/ml.

A rising value of CA 125 combined with gestational sac diameter that does not correspond to the pregnancy dating is highly significant in predicting the prognosis.

Serum estradiol was the next best marker with a sensitivity of 45% (95% CI 6–90%), a specificity of 87% (95% CI 81–92%), a positive likelihood ratio of 3.72 (95% CI 1.01–13.71) and a negative likelihood ratio of 0.62 (95% CI 0.20–1.84).


References:

https://humupd.oxfordjournals.org/content/22/2/228.abstract 

https://www.researchgate.net/publication/21703609_The_prognostic_significance_of_maternal_serum_CA125_measurement_in_threatened_abortion.





http://www.ncbi.nlm.nih.gov/pubmed/12235698